Prognostic value of autoantibodies in melanoma stage III patients in the EORTC 18991 phase III randomized trial comparing adjuvant pegylated interferon α2b vs observation

被引：1
|
作者：
Bouwhuis, M. G.
Suciu, S.
Testori, A.
Santinami, M.
Kruit, W. H.
Punt, C. J.
Sales, F.
Patel, P. M.
Spatz, A.
Eggermont, A. M. M.
机构：
[1] Erasmus MC Univ Med Ctr Rotterdam, Rotterdam, Netherlands
[2] EORTC Data Ctr, Dept Biostat, Brussels, Belgium
[3] European Inst Oncol, Milan, Italy
[4] Natl Canc Inst, I-20133 Milan, Italy
[5] Univ Med Ctr Nijmegen, Nijmegen, Netherlands
[6] Inst Jules Bordet, B-1000 Brussels, Belgium
[7] St James Univ Hosp, Canc Res UK Clin Ctr, Leeds, W Yorkshire, England
[8] Inst Gustave Roussy, Villejuif, France
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 06期
关键词：
D O I：
10.1016/S1359-6349(07)70098-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5LB
引用
收藏
页码：5 / 6
页数：2
相关论文
共 50 条
  • [21] Stage III melanoma and pegylated interferon alfa-2b therapy
    不详
    [J]. JOURNAL OF DRUGS IN DERMATOLOGY, 2008, 7 (08) : 809 - 809
  • [22] Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma: A Phase III Randomized Controlled Trial of Health-Related Quality of Life and Symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group
    Bottomley, Andrew
    Coens, Corneel
    Suciu, Stefan
    Santinami, Mario
    Kruit, Willem
    Testori, Alessandro
    Marsden, Jeremy
    Punt, Cornelis
    Sales, Francois
    Gore, Martin
    MacKie, Rona
    Kusic, Zvonko
    Dummer, Reinhard
    Patel, Poulam
    Schadendorf, Dirk
    Spatz, Alain
    Keilholz, Ulrich
    Eggermont, Alexander
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (18) : 2916 - 2923
  • [23] Adjuvant therapy with high-dose interferon α2b in patients with high-risk stage IIB/III melanoma
    Kirkwood, John M.
    Tarhini, Ahmad A.
    Moschos, Stergios J.
    Panelli, Monica C.
    [J]. NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (01): : 2 - 3
  • [24] Adjuvant therapy with high-dose interferon α2b in patients with high-risk stage IIB/III melanoma
    John M Kirkwood
    Ahmad A Tarhini
    Stergios J Moschos
    Monica C Panelli
    [J]. Nature Clinical Practice Oncology, 2008, 5 : 2 - 3
  • [25] Phase III randomized pilot study comparing interferon α-2b in combination with radiation therapy versus radiation therapy alone in patients with stage III-B carcinoma of the cervix
    Yazigi, R
    Aliste, G
    Torres, R
    Ciudad, AM
    Cuevas, M
    Garrido, J
    Prado, S
    Solá, A
    Castillo, R
    Cerda, B
    Cumsille, MA
    González, M
    Navarro, C
    Reyes, JM
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2003, 13 (02) : 164 - 169
  • [26] Intermittent high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III malignant melanoma: Final analysis of a randomized phase III DeCOG-trial (NCT00226408).
    Mohr, Peter
    Hauschild, Axel
    Trefzer, Uwe
    Enk, Alexander
    Tilgen, Wolfgang
    Loquai, Carmen
    Gogas, Helen
    Haalck, Thomas
    Koller, Josef
    Schadendorf, Dirk
    Dummer, Reinhard
    Gutzmer, Ralf
    Brockmeyer, Norbert
    Hoelzle, Erhard
    Sunderkoetter, Cord
    Mauch, Cornelia
    Stein, Anette
    Schneider, Lars
    Podda, Maurizio
    Weichenthal, Michael
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [27] Intermittent high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III malignant melanoma: An interim analysis of a randomized phase III study (NCT00226408)
    Mohr, P.
    Hauschild, A.
    Enk, A.
    Trefzer, U.
    Rass, K.
    Grabbe, S.
    Brockmeyer, N. H.
    Koller, J.
    Gogas, H.
    Weichenthal, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [28] Adjuvant pembrolizumab versus high-dose interferon α-2b for Chinese patients with resected stage III melanoma: a retrospective cohort study
    Tao Li
    Dong-Dong Jia
    Li-Song Teng
    [J]. Investigational New Drugs, 2020, 38 : 1334 - 1341
  • [29] Adjuvant pembrolizumab versus high-dose interferon α-2b for Chinese patients with resected stage III melanoma: a retrospective cohort study
    Li, Tao
    Jia, Dong-Dong
    Teng, Li-Song
    [J]. INVESTIGATIONAL NEW DRUGS, 2020, 38 (05) : 1334 - 1341
  • [30] Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma: A Phase III Randomized Controlled Trial of Health-Related Quality of Life and Symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group (vol 27, pg 2916, 2009)
    Bottomley
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (27) : 4630 - 4630
12345